23andMe and Genetech collaborate over Avastin markers; Parkinson's UK recruiting for biomarkers study;

> In the InVite study, the personal genomics company 23andMe is collaborating with Genentech to find genetic markers for responses to bevacizumab (Avastin) in the treatment of metastatic breast cancer. Website | Article

> As part of Parkinson's Awareness Week, Parkinson's UK is recruiting volunteers for the world's largest ever in-depth study of people with Parkinson's and their families, with an aim to find biomarkers for the disease. Article

> Mayo Clinic researchers have found a new type of molecular mutation that may shed new light on development and growth of different types of breast tumors. Release

> Florbetan as a tracer in PET imaging could spot amyloid plaques and help earlier Alzheimer's disease diagnosis. Article (reg. req.)

> Optical biomarkers may spot the patients who will progress from Barrett's esophagus to invasive cancer. Article

> RiboMed Clinical Services Laboratory has launched a multi-marker methylation prognostic test for grading gliomas. Press release

> Abbott has licensed biomarkers from Stanford University that could help to differentiate aggressive from nonaggressive prostate cancer. Press release

> NT5E has potential as a biomarker in primary and relapsed melanoma, as well as being a possible target for treatment. Abstract

> Metabolon and Takeda have created an alliance to focus on discovering therapeutic targets and biomarkers. Press release

> SOMALogic's SOMAscan proteomics technology has found a series of protein biomarkers in lung cancer. Press release

> Biomarker discovery is one of the targets for a new U.S. research team funded by Stand Up to Cancer. Article (reg. req.)

> Vermillion has received a patent for its urine biomarkers for ovarian cancer. Press release

And Finally… Genome BC is funding biomarker research at the Canadian PROOF Centre of Excellence to develop a blood test for a lung attack in COPD. Press release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.